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Impaired muscle blood flow at the onset of heavy-intensity exercise
may transiently reduce microvascular O2 pressure and decrease the
rate of O2 transfer from capillary to mitochondria in chronic heart
failure (CHF). However, advances in the pharmacological treatment
of CHF (e.g., angiotensin-converting enzyme inhibitors and third-
generation -blockers) may have improved microvascular O2 delivery
to an extent that intramyocyte metabolic inertia might become the
main locus of limitation of O2 uptake (V˙ O2) kinetics. We assessed the
rate of change of pulmonary V˙ O2 (V˙ O2p), (estimated) fractional O2
extraction in the vastus lateralis ([deoxy-HbMb] by near-infra-
red spectroscopy), and cardiac output (Q˙ T) during high-intensity
exercise performed to the limit of tolerance (Tlim) in 10 optimally
treated sedentary patients (ejection fraction  29  8%) and 11
controls. Sluggish V˙ O2p and Q˙ T kinetics in patients were significantly
related to lower Tlim values (P  0.05). The dynamics of [deoxy-
HbMb], however, were faster in patients than controls [mean re-
sponse time (MRT)  15.9  2.0 s vs. 19.0  2.9 s; P  0.05] with
a subsequent response “overshoot” being found only in patients
(7/10). Moreover, V˙ O2/MRT-[deoxy-HbMb] ratio was greater in
patients (4.69  1.42 s vs. 2.25  0.77 s; P  0.05) and related to Q˙ T
kinetics and Tlim (R  0.89 and 	0.78, respectively; P  0.01). We
conclude that despite the advances in the pharmacological treatment
of CHF, disturbances in “central” and “peripheral” circulatory adjust-
ments still play a prominent role in limiting V˙ O2p kinetics and
tolerance to heavy-intensity exercise in nontrained patients.
blood flow; chronic heart failure; hemodynamics; near-infrared spec-
troscopy; oxygen consumption
THE TIME COURSE IN WHICH pulmonary oxygen uptake (V˙ O2p)
adapts to dynamic exercise is characteristically slowed in
patients with chronic heart failure (CHF) compared with age-
matched controls (7, 58, 61). The slowed V˙ O2p kinetics (i.e.,
larger O2 deficit) lead to greater reliance on O2-independent
pathways for ATP regeneration and accumulation of by-prod-
ucts related to increased muscle fatigability (e.g., inorganic
phosphate and H) (2, 56). In fact, faster V˙ O2p kinetics after
selected therapeutic and rehabilitative strategies have been
associated with improved exercise tolerance in CHF patients
(12, 48, 63), suggesting that amelioration or resolution of the
impaired oxidative metabolism at the onset of exercise has
important clinical implications (as reviewed in Ref. 1).
It is widely recognized that disturbances in the diffusive
and/or convective transport of O2 to skeletal muscle mitochon-
dria (31, 41) and/or intramyocyte metabolic machinery (9, 25,
26) could explain the slowness of V˙ O2p kinetics in patients with
cardiopulmonary and metabolic disorders (7, 51, 61). In this
context, it can be anticipated that if the increase in muscle
microvascular O2 delivery (Q˙ O2mv) slows to a greater extent
than the rate of change in muscle V˙ O2 (as estimated by the
kinetics of the “primary” component of V˙ O2p) (2, 25, 56),
fractional O2 extraction [changes () in the deoxygenated
hemoglobin  myoglobin ([deoxy-HbMb]) signal by near-
infrared (NIR) spectroscopy (NIRS)] would be accelerated in
CHF patients (14, 22, 23, 28). Conversely, if the rate of
increase in fractional O2 extraction is slowed in CHF patients
at the onset of exercise, this would argue against a predominant
role of insufficient Q˙ O2mv in limiting V˙ O2 kinetics, thereby
suggesting that V˙ O2 dynamics are limited by a slow activation
of intracellular metabolic pathways (9, 25, 26).
The dynamic relationship between Q˙ O2mv and O2 utilization,
however, has been to date explored only in animal models with
nontreated CHF induced by myocardial infarction (5, 6, 18, 20,
35, 45). By using phosphorescence quenching to obtain intra-
vital measurements of microvascular PO2 (PO2mv) (59), previ-
ous investigators reported that CHF was indeed associated with
Q˙ O2mv-to-V˙ O2 mismatching, a finding that was modulated by
disease severity (18, 20), fiber typing (5, 45), and senescence
(6, 20). However, it is unknown whether these seminal obser-
vations are actually applicable to humans with naturally oc-
curring CHF receiving contemporary pharmacological treat-
ment. In fact, the last decades brought about major changes in
the treatment paradigms of CHF [e.g., angiotensin-converting
enzyme inhibitors (ACEIs)/angiotensin-receptor blockers
(ARBs) and -adrenergic blockers] (17, 32), which might be
effective in improving CHF-related endothelial dysfunction
(49, 55) and excessive sympathetic and neurohumoral activa-
tion (16, 19) with positive consequences on muscle blood flow
(52, 55). In fact, combined therapy with ACEIs and ARBs and
carvedilol, a -adrenergic antagonist with vasodilatory prop-
erties (
1-antagonism), is particularly emphasized in clinical
guidelines (17, 32). These recommendations were based on the
evidence that these drugs might work synergistically to im-
prove left ventricular (LV) ejection fraction and lessen LV
remodeling with positive consequences on hospitalizations and
Address for reprint requests and other correspondence: J. A. Neder,
Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE);
Respiratory Division, Dept. of Medicine; Federal Univ. of Sa˜o Paulo-
Paulista School of Medicine (UNIFESP-EPM), Rua Professor Francisco de
Castro 54, Vila Clementino, CEP 04020-050, Sa˜o Paulo, Brazil (e-mail:
albneder@pneumo.epm.br).
Am J Physiol Heart Circ Physiol 297: H1720–H1728, 2009.
First published September 4, 2009; doi:10.1152/ajpheart.00596.2009.
0363-6135/09 $8.00 Copyright © 2009 the American Physiological Society http://www.ajpheart.orgH1720
survival (17, 32, 53). However, the effects of CHF on the
dynamics of (estimated) muscle Q˙ O2mv-to-V˙ O2 matching at the
onset of exercise in optimally treated humans with naturally
occurring forms of the disease remain unknown.
The objective of the present study, therefore, was to inves-
tigate the relationship between the dynamics of Q˙ O2mv and O2
utilization at the onset of heavy-intensity exercise in nontrained
patients with advanced CHF receiving contemporary pharma-
cological therapy. We tested the hypothesis that the therapeutic
advances in the treatment of CHF (17, 32) might have im-
proved Q˙ O2mv to an extent that the slowness of intramyocyte
metabolic machinery would become the limiting step of V˙ O2p
kinetics. For this purpose, we simultaneously assessed the rate
of change of V˙ O2p, [deoxy-HbMb], and cardiac output (Q˙ T)
during an exercise bout performed above the gas-exchange
threshold (GET) to the limit of tolerance (Tlim) in a group of
CHF patients and age-matched controls. We reasoned that
knowledge of the precise etiological mechanisms leading to the
microcirculatory O2 exchange impairment in CHF is crucial to
understanding the mechanisms of exercise intolerance and the
planning of effective rehabilitative strategies aimed to decrease
its clinical burden in this patient population.
METHODS
Subjects
This was a prospective study involving 10 nonsmoking men re-
cruited from the CHF Outpatients Clinic of our institution and 11 age-
and sex-matched controls. Patients had an established diagnosis of
CHF for at least 4 yr, three-dimensional echodopplercardiography
showing left ventricle ejection fraction (LVEF)  35%, and New
York Heart Association classification scores II–III. The patients have
been optimally treated for CHF for at least 3 yr (Table 1) according to
the American Heart Association/American College of Cardiology
treatment recommendations for stage “C” patients, i.e., reduced LVEF
and current or previous symptoms of heart failure (32). No patients
had a history of hospitalization or disease exacerbation in this time-
frame. Patients were excluded from study if they had clinical and/or
functional evidences of obstructive pulmonary disease (forced expi-
ratory volume in 1 s-to-forced vital capacity ratio ( 0.7) anemia
([Hb]  13 g%), exercise-induced asthma, diabetes mellitus or other
metabolic diseases, unstable angina or significant cardiac arrhythmias,
and myocardial infarction within the previous 12 mo. To avoid the
confounding effects of physical activity on the determinants of V˙ O2p
kinetics (56), no patient had ever been submitted to cardiovascular
rehabilitation. The control group was also carefully selected to recruit
subjects who had not take part into any exercise training program in
the preceding 5 yr and had no regular physical activity either at work
or during leisure time. Subjects were required to be free of chronic
pulmonary, cardiovascular, immune, and metabolic diseases. Prior to
entering the study all healthy controls were submitted to clinical
evaluation and they were screened by pulmonary function tests,
analysis of blood biochemistry, electrocardiography, echocardiogra-
phy, and a stress exercise testing. Study participants gave written,
informed consent, and the study protocol was approved by the
Institutional Medical Ethics Committee.
Study Protocol
After familiarization, subjects performed a ramp-incremental exer-
cise test (5–10 W/min in patients and 15–20 W/min in controls) to
determine parameters of aerobic function during exercise. The difference
between V˙ O2p at the GET and V˙ O2p at peak exercise (V˙ O2ppeak-GET) was
determined. On a different day, subjects were submitted to a constant-
work-rate exercise test to the Tlim (s) at a V˙ O2p equivalent to
40 –50% of the V˙ O2ppeak-GET [70 – 80% peak work rate]. Tlim
was defined as the time point at which subjects signaled to stop
exercising or could not maintain the required pedaling rate for 10 s
despite being encouraged by the investigators. Subjects avoided
caffeine, alcohol, or heavy meals before testing.
Measurements
Exercise tests. The tests were performed on an electronically
braked cycle ergometer (Corival 400, Lode, The Netherlands) at 60
rpm and they were preceded by an unloaded baseline pedaling at 0 W
for 2 min. V˙ O2p (ml/min), V˙ CO2p (pulmonary carbon dioxide output,
ml/min), minute ventilation (V˙ E, l/min), and end-tidal partial pressures
(PET) for O2 and CO2 (mmHg) were measured breath by breath using
a computer-based system (CardiO2 System, Medical Graphics). Gas-
exchange variables measured during the incremental test were aver-
aged every 15 s. V˙ O2ppeak was defined as the highest value achieved
during the test and compared with Brazilian standards (50). Heart rate
(HR, bpm) was determined by using the R-R interval from a 12-lead
electrocardiogram. Arterial oxyhemoglobin saturation was determined
by pulse oximetry (%; POX 010–340, Mediaid) with its analog signal
being directed to the system. Subjects were also asked to rate their
“shortness of breath” at exercise cessation using the 0–10 Borg’s
category-ratio scale. The V˙ O2pGET was estimated by the gas-exchange
method, inspecting visually the inflection point of V˙ CO2p with regard
to V˙ O2p (modified V-slope) and secondarily confirmed by the venti-
latory method when V˙ E/V˙ O2p and PETO2 increased while V˙ E/V˙ CO2p
and PETCO2 remained stable. The reading was performed indepen-
dently by two experienced observers without knowledge of other
results or subject identities.
Skeletal muscle oxygenation. Skeletal muscle oxygenation profiles
of the left vastus lateralis were evaluated with a commercially avail-
able NIRS system (Hamamatsu NIRO 200, Hamamatsu Photonics).
Table 1. Resting and exercise data from healthy subjects
and optimally treated patients with CHF
Controls, n 11 CHF, n 10
Anthropometrics/demographics
Age, yr 62.45.9 60.98.8
Body mass, kg 78.415.9 76.913.7
Body mass index, kg/m2 23.93.8 22.54.1
Echocardiography
Left ventricle ejection fraction, % 59.75.0 29.18.2*
Drugs
Diuretics 7
Spironolactone 4
Digitalis 5
Carvedilol 10
ACE inhibitors/AR blockers 10
Incremental exercise
Power, W 13219 8314*
V˙ O2p, ml/min 1,708204 1,315192*
V˙ O2p, ml  min	1  kg	1 23.14.2 15.12.8*
V˙ O2p, % pred 88.910.1 53.119.4*
V˙ O2pGET, ml/min 1,080175 785128*
HR, bpm 15312 13410*
HR, % pred 95.34.7 74.110.9*
Constant work rate exercise
Power, W 9013 5812*
Time to exercise intolerance, s 495168* 315103
V˙ O2p, ml/min 1,684181 1,292200*
HR, bpm 14510 1309*
SV, ml 104.316.1 80.214.3*
Q˙ T, l/min 14.82.1 9.92.4*
Values are means  SD. CHF, chronic heart failure; ACE, angiotensin-
converting enzyme; AR, angiotensin-receptor; V˙ O2p, pulmonary oxygen up-
take; GET, gas-exchange threshold; HR, heart rate; SV, stroke volume; Q˙ T,
cardiac output. *P  0.05 (nonpaired t-test).
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The theory of NIRS has been described in detail elsewhere (21).
Briefly, one fiber optic bundle carried the NIR light produced by the
laser diodes to the tissue of interest while a second fiber optic bundle
returned the transmitted light from the tissue to a photon detector in
the spectrometer. The intensity of incident and transmitted light were
recorded continuously and, along with the relevant specific extinction
coefficients, used to measure changes in the oxygenation status of Hb
and Mb. A set of optodes was placed on the belly of the vastus
lateralis muscle midway between the lateral epicondyle and greater
trochanter of the femur. The optodes were housed in an optically
dense plastic holder, thus ensuring that the position of the optodes,
relative to each other, was fixed and invariant. The optode assembly
was secured on the skin surface with tape and then covered with an
optically dense, black vinyl sheet, thus minimizing the intrusion of
extraneous light and loss of NIR light.
The variables assessed by NIRS are the concentration (denoted by
square brackets) of oxygenated, deoxygenated, and total Hb. Among
the NIRS variables, several laboratories have adopted the [deoxy-
HbMb] signal as the preferred indicator of changes in muscle
microvascular oxygenation during exercise (11, 14, 23, 28). The
[deoxy-HbMb] response to exercise is then considered a proxy of
fractional O2 extraction in the microcirculation, reflecting the balance
between O2 delivery and utilization. The device used herein did not
measure the reduced-scattering of the tissue (36), preventing determi-
nation of absolute values of [deoxy-HbMb] (in M). Therefore,
values were recorded as a delta () from baseline in units of micro-
molar per centimeter and expressed relative (%) to the amplitude of
variation from baseline to the steady state.
Central hemodynamics. Q˙ T (l/min) and stroke volume (SV, liters)
were measured noninvasively throughout the constant work rate test
by impedance cardiography (PhysioFlow PF-05, Manatec Biomedi-
cal). The PhysioFlow device and its methodology have been thor-
oughly described elsewhere (10). This methodology is different from
previously used impedance systems as its algorithm does not require
basal thoracic impedance measurement (Z0). Before each exercise
test, the system was autocalibrated taking into consideration age,
stature, body mass, and blood pressure values. Signal quality was
verified by visualizing the electrocardiography (ECG) tracing and its
first derivative (dECG/dt) and the impedance waveform (Z) with its
first derivative (dZ/dt). In preliminary experiments the coefficient of
variation for changes in Q˙ T and SV during exercise were 3.3 and
4.1%, respectively. In these preliminary trials the changes in Q˙ T
measured by impedance cardiography were consistent with those
predicted from V˙ O2p values using the submaximal Q˙ T-V˙ O2p relation-
ship described in CHF patients (8).
Kinetics analysis. The breath-by-breath V˙ O2p, [deoxy-HbMb]
and hemodynamic (Q˙ T, SV, and HR) data were time aligned to the
start of exercise and interpolated second by second. The kinetics of
these responses were determined by nonlinear regression using a least
square technique (Marquardt-Levenberg, SigmaPlot 10.0, Systat Soft-
ware). The V˙ O2p responses to exercise in the intensity domain used in
our investigation are characterized by the presence of a slow compo-
nent (2, 56). We checked the absence of the onset or emergence of the
slow component in the first 180 s after the start of exercise by
certifying that the monoexponential fit (Eq. 1) did not demonstrate a
discernible departure from the measured response profile, i.e., main-
tenance of the flat profile of the residual plot. If the slow component
was not discernible, we opted to fit V˙ O2p from 30 s of baseline
pedaling to the steady-state value; otherwise, data were fitted from
30 s of baseline pedaling to 180 s after the onset of exercise. For
[deoxy-HbMb] kinetics the analyses were conducted on data from
30 s of baseline cycling to the steady-state response to minimize
distortion of the curve-fitting seen when longer periods are analyzed.
Theoretical (22) and empirical studies (11, 14, 23, 28) suggest that the
primary phase of the [deoxy-HbMb] response is complete within
this time window.
The model used for fitting the kinetic response of V˙ O2p and
[deoxy-HbMb] was
[Y]t [Y]b A  1 e	t	TD/ (1)
where b refers to baseline unloaded cycling and A, TD, and  are the
amplitude, time delay, and time constant of the exponential response,
respectively. For V˙ O2p analysis we deleted the data relative to the
cardiodynamic phase, which duration was individually determined
according to standard procedures (2). Therefore, V˙ O2p represents the
time course of the primary component 	 an estimate of the muscle
V˙ O2 kinetics (25) (see Methodological Considerations and Interpre-
tative Issues). The overall kinetics of [deoxy-HbMb] (time to
reach 63% of the response following the onset of exercise) were
determined by the mean response time (MRT    TD). To relate
the kinetics of O2 utilization to the dynamics of (estimated) fractional
O2 extraction, we calculated the ratio V˙ O2p/MRT-[deoxy-HbMb].
Therefore, the higher this ratio, the faster the [deoxy-HbMb]
kinetics in relation to V˙ O2p dynamics, suggesting slower adaptation of
Q˙ O2mv (11). For the hemodynamic data, we opted to calculate the
individual half-time (t1/2, s) as the low signal-to-noise ratio for SV and
Q˙ T precluded an adequate monoexponential fitting in some patients.
This parameter was defined as the time in which the physiological
response reached half of the difference between 180 s and the onset of
exercise (SigmaPlot 10.0). An estimate of MRT was then obtained as
t1/2  1.44.
Based on previous findings with other disease populations (3, 11),
we systematically looked at the presence or not of an “overshoot” in
[deoxy-HbMb] after the initial “fast” response (see RESULTS). A
two-component, monoexponential model was applied to these data:
[Y]t [Y]b A1  1 e	t	TD1/1 A2  1 e	t	TD2/2 (2)
where the subscripts 1 and 2 correspond to the two sequential
components (upward and downward, respectively). This model was
applied to adequately define the duration of the upward component,
i.e., TD2. Considering, however, the uncertainties about the actual
physiological meaning of the downward component, only the describ-
ing parameters of the upward component were considered for statis-
tical analysis. Assuming that a larger area under the [deoxy-
HbMb] overshoot would be conceptually similar to a greater “un-
dershoot” in the PO2mv (22, 23, 57), the former variable was used as
an additional index of impaired microvascular O2 delivery. On pre-
liminary trials, the coefficient of variation for the kinetic parameters of
the [deoxy-HbMb] response ranged between 5–11% [1st test 	
2nd test mean bias and range:   0.3 s (	0.3 s to 0.8 s) and TD 
0.1 s (	0.4 to 0.5 s)].
Statistical Analysis
Results were summarized as means  SD. To contrast between-
subject resting and exercise responses, nonpaired t or Mann-Whitney
tests were used as appropriate. Pearson’s product moment correlation
was used to assess the level of association between continuous
variables. The level of statistical significance was set at P  0.05 for
all tests.
RESULTS
Subject Characteristics and Maximal Exercise Capacity
There were no significant differences on anthropometric
attributes in CHF patients vs. age-matched controls (Table 1).
Etiology of CHF was mostly nonischemic and patients had
severe LV dysfunction at rest. In contrast, peak work rate and
peak V˙ O2p were only moderately reduced with eight patients
being classified as Weber’s class II and two patients as class
III. The GET was identified in all subjects, and patients had
lower V˙ O2pGET than controls (P  0.05). Patients showed
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impaired chronotropic responses and lower tolerance to con-
stant work-rate exercise (Tlim) compared with controls (Table
1; P  0.01).
Pulmonary Gas Exchange and Cardiovascular Dynamics
The kinetics of V˙ O2p and hemodynamic responses were
slower in patients than controls (Fig. 1 for V˙ O2p and Q˙ T; Table 2).
In a subgroup of subjects in whom the tests were repeated (6 patients
and 6 controls), the coefficient of variation for V˙ O2p and t1/2 Q˙ T
averaged 8.4 and 9.9%, respectively. Estimated MRT-Q˙ T was con-
sistently slower than V˙ O2p in both groups (P 0.05) (Fig. 1; Table
1). MRT-HR was particularly impaired in patients compared
with controls (CHF-controls/controls  100  84.7  32.3%
and 34.7  19.5% for HR and SV responses, respectively).
There was a significant relationship between V˙ O2p and t1/2 Q˙ T
only in patients (R  0.79); in addition, both variables were
related to Tlim in CHF patients (R  	0.81 and R  	0.69,
respectively; P  0.05) but not in controls.
Muscle Oxygenation and Estimated Q˙ O2mv
The [deoxy-HbMb] response displayed a region in which
the signal remained stable or decreased transiently with similar
duration in both groups (time delay). After this phase, [deoxy-
HbMb] increased rapidly with a response kinetics that were
much faster than the V˙ O2p and Q˙ T responses in both groups
(Figs. 1 and 2; Table 2).
There were substantial differences in the [deoxy-HbMb]
dynamics in patients vs. controls. Therefore, [deoxy-
HbMb] (Figs. 1 and 2; Table 2) and MRT-[deoxy-HbMb]
(Fig. 2) were significantly faster in patients compared with
controls (P  0.05). In addition, V˙ O2/MRT-[deoxy-
HbMb] was greater in patients (4.69  1.42 s vs. 2.25 
0.77 s; P  0.05) and an overshoot in the [deoxy-HbMb]
response was found in 7 of 10 patients but in no control (see
Fig. 2 for a representative patient).
There was a significant relationship between V˙ O2/MRT-
[deoxy-HbMb] and the area under the overshoot in these
patients (R  0.74; P  0.05). Importantly, V˙ O2/MRT-
[deoxy-HbMb] was also significantly related to both t1/2 Q˙ T
and Tlim (Fig. 3) in CHF patients.
DISCUSSION
This is the first study, to our knowledge, to investigate
whether the dynamic matching of (estimated) Q˙ O2mv and V˙ O2
at the onset of heavy-intensity exercise is impaired in optimally
treated (17, 32) humans with CHF. We found that phase II
Fig. 1. Mean response time of pulmonary V˙ O2 (V˙ O2p), cardiac output (Q˙ T),
and changes in deoxy-hemoglobinmyoglobin measured by near-infrared
spectroscopy ([deoxy-HbMb]; fractional O2 extraction) at the onset of
heavy-intensity exercise in age-matched sedentary controls (shaded bars) and
optimally treated patients with chronic heart failure (CHF) (solid bars). Note
that the kinetics of V˙ O2p and Q˙ T were slower in CHF patients; in contrast,
patients presented with faster [deoxy-HbMb] dynamics compared with
healthy controls, suggesting impaired microvascular O2 delivery. Data are
means (SD). *P  0.05 for between-group comparisons; †P  0.05 for
within-group comparisons of V˙ O2p vs. Q˙ T; ‡P  0.05 for within-group
comparisons of [deoxy-HbMb] vs. V˙ O2p and Q˙ T.
Fig. 2. [deoxy-HbMb] at the onset of heavy-intensity exercise in a repre-
sentative age-matched control (CTL) and an optimally treated patient with
CHF. Values are expressed relative to the amplitude of variation from baseline
to the steady state. Note the signal “overshoot” after a more rapid rate of
change in [deoxy-HbMb] [i.e., lower mean response time (MRT   
TD)] in the CHF patient, suggesting a faster kinetics of fractional O2 extraction
and impaired microvascular O2 delivery. TD, time delay; , time constant.
Table 2. Kinetic parameters for V˙ O2p, deoxy-HbMb,
and Q˙ T by transthoracic impedance in healthy subjects and
optimally treated patients with CHF
Controls, n 11 CHF, n 10
V˙ O2p
Baseline, ml/min 484123 409108
Amplitude, ml/min 908134 584149*
, s 40.511.3 65.316.7*
TD, s 10.88.7 9.510.1*
deoxy-HbMb
Baseline, % 0.12.1 	0.41.9
Amplitude, % 96.47.5 114.29.3*
, s 9.31.6 5.91.7*
TD, s 10.71.9 10.02.0
Q˙ T
Baseline, l/min 6.51.9 4.91.7*
Amplitude, l/min 5.21.5 3.11.3*
t1/2, s 40.27.5 70.713.0*
Values are means  SD. deoxy-HbMb, changes in deoxy-
hemoglobinmyoblobin by near-infrared spectroscopy; TD, time delay; ,
time constant; t1/2, half-time. deoxy-HbMb values expressed relative to
steady-state, baseline variation. *P  0.05 (nonpaired t-test).
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V˙ O2p kinetics were slower in patients than controls and signif-
icantly related to decreased exercise tolerance (Tlim). Patients
also displayed sluggish kinetics of Q˙ T and faster dynamics of
fractional O2 extraction ([deoxy-HbMb] by NIRS) (11,
14, 23, 28), suggesting impaired adaptation of Q˙ O2mv. This
contention was further supported by the findings of higher
values of the V˙ O2p/MRT-[deoxy-HbMb] ratio in patients,
i.e., for a given rate of change in V˙ O2p, [deoxy-HbMb]
adapted more rapidly in patients than controls. Moreover, an
overshoot in [deoxy-HbMb] signal was found in 7 of 10
patients but in none of the controls. Importantly, higher V˙ O2p/
MRT-[deoxy-HbMb] values were associated with slower
dynamics of Q˙ T and shorter Tlim (Fig. 3), suggesting that the
slowness of Q˙ O2mv kinetics have been mechanistically linked to
the sluggish “central” cardiovascular adjustments and contrib-
uted to decreased exercise tolerance. These data, therefore,
provided evidence that contemporary pharmacological therapy
(17, 32) does not preclude that central and “peripheral” circu-
latory disturbances still play a prominent role in limiting the
initial rate of change in the muscle oxidative metabolism and
tolerance to high-intensity exercise in humans with CHF.
Mechanisms for Slower V˙ O2p Kinetics in Humans With CHF
It has long been demonstrated that the dynamics of V˙ O2p are
slowed in patients with CHF (7, 61) and related to a number of
clinical and functional outcomes (1, 12, 48, 63). In this context,
derangements of convective and diffusive O2 delivery to mi-
tochondria (i.e., O2 transport) and/or impaired muscle utiliza-
tion (i.e., intramyocyte metabolic inertia) may account for the
prolonged V˙ O2p kinetics (56). Potential mechanisms leading to
impaired O2 delivery include the central hemodynamic effects
of CHF (46, 62), heightened neurohumoral activation (16, 49),
impaired nitric oxide- (24) and endothelium-dependent (4)
vasodilation, and/or impaired blood flow redistribution from
the nonexercising tissues to the exercising muscles (47).
Conversely, CHF is also associated with profound bioener-
getic disturbances in the skeletal muscles that could also limit
the rate of increase in V˙ O2p (15). For instance, V˙ O2p kinetics are
not always accelerated in heart transplant recipients (39) and
remain abnormal during small muscle mass exercise in which
the central cardiovascular constraints are no longer operative
(33). In addition, increased Q˙ T after cardiac reinnervation has
not been consistently associated with faster V˙ O2p kinetics (43).
Further evidence for a relevant role of intramuscular factors
was provided by Zelis et al. (66), who found slower rates of
NIRS-measured muscle deoxygenation during arterial occlu-
sion in patients with severe CHF and by the findings of
Diederich et al. (18) and Behnke et al. (6), who described
slower, rather than faster, rates of decrease in PO2mv in rat with
severe vs. moderate CHF.
In the clinical context, this issue is further complicated by
the potential effects of contemporary pharmacological treat-
ment of CHF on the main determinants of O2 delivery in
patients with CHF. More specifically, ACEIs and ARBs plus
-blockers have been found to be effective in improving
CHF-related endothelial dysfunction (49, 55) and reduce ex-
cessive sympathetic outflow to the limbs (16, 19) with positive
effects on muscle blood flow (52, 55). Collectively, these data
might indicate that such improvements in CHF treatment may
have enhanced the dynamics of muscle O2 delivery to an extent
that intramuscular metabolic inertia would become the main
factor limiting V˙ O2p kinetics. Several variables measured and
estimated in our study suggest that this may not be the case
during exercise of heavy intensity in nontrained men with
stable CHF.
Microvascular O2 Delivery During Exercise in CHF
Our data demonstrated that CHF patients showed faster
kinetics of muscle microvascular fractional O2 extraction (as
estimated by [deoxy-HbMb]) and slower kinetics of phase
II than controls, suggesting that Q˙ O2mv adapted at a slower rate
in patients (14, 22, 23, 28). Moreover, the ratio V˙ O2p/MRT-
[deoxy-HbMb] was closely related to the overall kinetics of
central cardiovascular adjustments and exercise tolerance (Fig.
3). These results are of particular clinical relevance because the
patients have been therapeutically optimized for at least 3 yr
(17, 32) and the confounding effects of training status and
comorbidities (such as anemia and diabetes) have been care-
fully avoided. It is appropriate, however, to point out that the
order of speed of responses was similar in patients and con-
trols, i.e., [deoxy-HbMb], V˙ O2p, and Q˙ T (Fig. 1). Conse-
quently, it is conceivable that insufficient rates of muscle O2
Fig. 3. Relationship between time constant of the “primary” component of the
on-transient V˙ O2p/MRT of [deoxy-HbMb] with the dynamics of Q˙ T (A) and
time to exercise intolerance (Tlim) (B) in optimally treated patients with CHF
(F) and healthy controls (E). These data suggest that the sluggish kinetics of
microvascular O2 delivery have been mechanistically linked to slower “cen-
tral” cardiovascular adjustments (A) and contributed to decreased exercise
tolerance in CHF patients (B).
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delivery also limited the rate of increase in V˙ O2, albeit in a
lesser extent, in our middle-aged to aged controls (6, 20).
NIRS is a noninvasive technique that allows continuous
measurement of key determinants of peripheral muscle oxy-
genation during exercise (21). The time course of [deoxy-
HbMb] in particular reflects the local balance between O2
delivery and uptake in the area under investigation (14, 22, 23,
28). Several studies have shown that [deoxy-HbMb] pro-
vides a surrogate of fractional O2 extraction (see Methodolog-
ical Considerations and Interpretative Issues), and its mea-
surement in parallel with (muscle) phase II V˙ O2p kinetics can
give useful inferences regarding Q˙ O2mv via the Fick principle
(14, 22, 23, 28). In this context, it is widely recognized that the
muscle hemodynamic response at the onset of exercise is
characterized by a fast “phase I” response related to the
mechanical effect of muscle contraction (i.e., muscle pump)
and, probably, rapid vasodilation and a slower “phase II”
matched with metabolic demand, resulting from metabolic
feedback control (60). In contrast, muscle V˙ O2 response ap-
pears to be well characterized by a single monoexponential
function from the start of exercise (2). Therefore, the resulting
response of fractional O2 extraction ([deoxy-HbMb])
encompass an early delay where O2 delivery meets (or ex-
ceeds) demand (TD) and a rapidly increasing response when
the dynamics of capillary flow blood is slower than the rate of
change in O2 utilization (57). In this construct, the overall
[deoxy-HbMb] kinetics are expected to be inversely related
to the dynamics of Q˙ O2mv (14, 22, 23, 28).
In the present study, CHF patients showed faster overall
[deoxy-HbMb] kinetics (i.e., lower MRT values) due to a
more rapid rates of change () despite unaltered TD values.
Consequently, it seems that the phase II of microvascular blood
flow has been particularly impaired in our patients (22, 23). In
line with this notion, we observed a transient overshoot in the
[deoxy-HbMb] response after the initial “fast” response in
most CHF patients (Fig. 2), suggesting that estimated fractional
O2 extraction increased above the steady-state level because of
impaired muscle blood flow relative to V˙ O2 (3, 22, 23, 57).
Interestingly, this pattern of response is qualitatively similar to
the undershoot in the capillary PO2 responses previously ob-
served in the exercising muscle of diabetic (54) and CHF
animals (5, 6, 18, 35) and identical to the [deoxy-HbMb]
profiles described in patients with Type 2 diabetes (3) and
chronic obstructive pulmonary disease (11). This specific pat-
tern of response is thought to be related to a transient lowering
of capillary PO2 that seems to be large enough to reduce the
diffusion gradient from capillary to mitochondria thereby im-
pairing O2 flux and constraining the rate of increase in muscle
V˙ O2 (22, 23, 57).
Our results add novel information to previous studies that
used NIRS-based measurements during incremental (65) or
small muscle mass exercise (44) in patients with CHF. In fact,
the single study that has looked at the kinetics of [deoxy-
HbMb] at the onset of moderate-intensity exercise (40)
evaluated CHF patients after heart transplantation. Interest-
ingly, these authors did not find significant differences in
[deoxy-HbMb] kinetics in recipients vs. normal controls,
despite slower V˙ O2p kinetics in patients (40). These findings
suggest that the metabolic abnormalities in the skeletal muscles
were the main mechanism leading to slower V˙ O2p kinetics in
their subjects which is at marked variance with the present
findings in less severe patients. Conversely, our data are
consistent with previous animal studies that suggest that the
behavior of PO2mv (and, conceivably, [deoxy-HbMb] on the
inverse direction) is critically influenced by disease severity in
rats with CHF, i.e., faster PO2mv kinetics associated with a
signal undershoot in moderate CHF and slower PO2mv dynam-
ics without undershoots in more advanced CHF (6, 18). These
findings were interpreted as evidence that severe CHF has been
associated with proportional impairments in Q˙ O2mv and muscle
oxidative metabolism with the net effect being slower rather
than faster rates of change in PO2mv (6, 18).
There are several putative explanations by the persistently
abnormal Q˙ O2mv kinetics at the onset of exercise despite
optimal medical therapy. Firstly, Q˙ T kinetics were significantly
slower in CHF patients than controls (Fig. 1, Table 2). In this
context, the strong cardiac 2-blocking effect of carvedilol was
likely to be instrumental (19) because MRT-HR was 80%
lower in patients than controls. A study with “old,” nonselec-
tive -blockers did find a slowing effect on-exercise V˙ O2p
kinetics (30), and Guazzi and Agostoni (29) reported that
carvedilol failed to accelerate V˙ O2p kinetics in moderately
impaired patients with CHF. In fact, despite positive effects on
mortality (53), most of the large randomized controlled trials
actually failed to demonstrate a significant effect of newer
-blockers upon submaximal exercise tolerance (19). The
positive effects of carvedilol-related 
-adrenergic blockade on
vascular tone might have also vanished over time (37). Note-
worthy, patients’ therapy had been optimized according to
current clinical guidelines (17, 32) that do not include a
formal assessment of pulmonary gas-exchange kinetics to
titrate the prescribed doses of medication. Consequently, we
cannot rule out that would be necessary higher doses of
ACEIs and ARBs to counterbalance the potentially deleteri-
ous effects of -blockade in the Q˙ O2mv dynamics at the on-
exercise transient. Secondly, despite potential improvements in
central cardiovascular performance, pharmacological treatment
may have failed to ameliorate the impairment in muscle mi-
crovascular function in CHF (49, 55). In fact, a recent study
combining NIRS and 31P magnetic resonance spectroscopy
found that the recovery kinetics of [deoxy-HbMb] were
slower than that of phosphocreatine after single-leg extension
exercise in well-treated New York Heart Association class
II–III patients (34). These findings suggest that impaired mi-
crovascular function might have contributed to limit muscle O2
availability because the exercise paradigm was not associated
with substantial increases in the central cardiovascular de-
mands. Finally, patients were submitted to supra-GET exer-
cise, thereby predisposing V˙ O2p kinetics to be delivery limited
(56). However, this exercise intensity domain was deemed the
most adequate to test the main study hypothesis since it would
pose a higher-than-usual burden to the cardiovascular system
under treatment. In fact, despite the exercise test has been
performed at submaximal intensities, V˙ O2p at Tlim was quite
similar to peak V˙ O2p (Table 1), suggesting the development of
a marker of heavy-intensity exercise, i.e., the V˙ O2p “slow”
component (56).
Methodological Considerations and Interpretative Issues
Because of the cross-sectional and noninvasive nature of the
present investigation, several methodological and interpreta-
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tive aspects merit further clarification. We, like others (14, 22,
23, 28), assumed that the kinetics of [deoxy-HbMb] mea-
sured at a single site reflects the time course of muscle
fractional O2 extraction following the onset of exercise. How-
ever, there exists substantial heterogeneity on the distribution
of muscle blood flow and V˙ O2 (36) that might be more relevant
in the poorly perfused muscles of CHF patients. Consequently,
it is unlikely that a single-site evaluation provides a full
depiction of the complete range of individual intramuscular
Q˙ O2mv-to-V˙ O2 relationships. It should also be acknowledged
that the lowering effect of CHF on capillary O2 driving
pressure is less prominent in fast- rather than slow-twitch fibers
(5). Considering the higher proportion of fast-twitch fibers in
the quadriceps of the elderly (6) and patients with CHF (5), we
may have underestimated the speeding effect of CHF on the
rate of increase in muscle fractional O2 extraction.
A key argument in favor of the [deoxy-HbMb] response
as a noninvasive surrogate of fractional O2 extraction dynamics
is the similar characteristics of [deoxy-HbMb] changes
compared with fractional O2 extraction dynamics calculated in
computer simulations (23) and measured in skeletal muscles
(27). However, no previous study has confirmed these assump-
tions in patients with CHF. Another point of concern is the
potential interpopulation differences in the relative contribu-
tion of Mb to the [deoxy-HbMb] signal (42, 64), which
might have also impacted on the magnitude and rate of change
in muscle deoxygenation. In this context, Lai et al. (38), using
a systems biology approach, reported that the Mb contribution
to the whole NIRS signal is particularly relevant during hyp-
oxia compared with normoxia. Assuming that the skeletal
muscles contract under more hypoxic conditions in CHF pa-
tients than healthy controls, we cannot rule out that the Mb
contribution to [deoxy-HbMb] was higher in patients.
However, Mb has lower P50 values than Hb, an effect that
would tend to slow, not accelerate (Table 2, Fig. 2), the rate of
muscle deoxygenation in the CHF patients.
We used the kinetics of the primary component of V˙ O2p
response as an indicator of the muscle V˙ O2 response (2, 25).
However, it should be acknowledged that the fitting of a single
exponential, though statistically justifiable, is not evidence of
similar metabolic mechanisms in the two populations, espe-
cially during heavy-intensity exercise. More specifically, it is
unlikely that the relative contribution of anaerobic glycolysis to
ATP regeneration was equivalent in patients and controls (56).
We also recognize that slowing of muscle blood flow may
create a temporal dissociation between muscle and pulmonary
V˙ O2 kinetics, with the V˙ O2p response becoming faster than the
muscle V˙ O2 dynamics because of changes in the leg-to-lung
transit delay (2). Accordingly, we may have underestimated the
slowness of muscle V˙ O2 kinetics in CHF patients performing
heavy-intensity exercise. Our investigative approach, there-
fore, used noninvasive methods and was based on several
assumptions; consequently, we could only infer the rate of
muscle O2 delivery.
There are some clinical considerations that should be
stressed to avoid a widespread extrapolation of our results.
Several investigators reported that the likelihood of severe
intramyocyte disturbances is increased in patients with end-
stage disease (33, 40) and rats with severe CHF (6, 18).
Considering that our patients were only moderately impaired
(despite severe LV dysfunction by echodopplercardiography)
(Table 1), it remains to be tested whether the present results
hold true for humans with more advanced disease. However,
our sedentary patients had never been submitted to cardiac
rehabilitation, predisposing them to severe impairment in mus-
cle oxidative metabolism. We also admit that the response
overshoot in [deoxy-HbMb] (or PO2mv undershoot) is more
likely to be found in older subjects (6, 20) than those evaluated
in the present study (Table 1). Therefore, our results should be
viewed under the perspective that the aging process underlies
the behavior of [deoxy-HbMb] and V˙ O2p in both groups
and further studies are warranted to confirm the present find-
ings in younger CHF patients. In relation to the fitting approach
to [deoxy-HbMb] overshoot, it needs to be stressed that a
single monoexponential model was used merely for conve-
nience of comparisons and a higher-order model might have
better described the observed response profile (Fig. 2).
According to current guidelines, no patient in the present
study had clinical indication for resynchronization therapy or
LV assist device; nevertheless, it remains to be tested whether
the add-on therapy with these nonpharmacological strategies
would positively impact on (estimated) Q˙ O2mv kinetics. Fi-
nally, care should be taken to extrapolate our results for
patients with CHF secondary to ischemic heart disease since
CHF etiology may impact on the determinants of exercise
tolerance in this patient population (13).
Conclusions
The dynamic matching between O2 delivery to, and O2
uptake by, the peripheral muscles is significantly impaired at
the transition to heavy-intensity exercise in patients with CHF
who had been adequately treated with the best-available phar-
macological therapy. These abnormalities are closely related to
the derangements on the central cardiovascular adjustments to
exertion. Our data, therefore, indicate that despite the remark-
able advances in clinical management of CHF, disturbances in
the cardiocirculatory responses still play a prominent role in
limiting V˙ O2p kinetics and tolerance to heavy-intensity exercise
in humans with naturally occurring forms of the disease.
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